← Leaderboards
Mace L Rothenberg
Vanderbilt University
$4,992,407
Attributed
$4,992,407
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2005–11$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$4,992,407 · 10
By mechanism
P50$2,993,798 · 3
K24$1,111,000 · 1
U01$580,717 · 1
R21$306,300 · 1
M01$592 · 4
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Albert Craig Lockhart$3,804,812
- Josh F. Peterson$25,101,962
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchNeoplasm /Cancer ChemotherapyHuman SubjectHuman Therapy EvaluationGrantTranslational ResearchClinical Trial Phase IPharmacokineticsAntineoplasticsClinical TrialsDesignEpidermal Growth Factor ReceptorMalignant NeoplasmsBiopsyTumorReproduction SporesColorectal CancerIrinotecanDrug Screening /EvaluationNeoadjuvant TherapyCollaborationsKinase InhibitorEastern Cooperative Oncology GroupData Management
Grant awards (50)
Implications of Blockade of EGFR Axis & Src in Colorectal Cancer$312,120
P50 · FY2011 · CA · contact PI
Clinical Trials$156,744
P50 · FY2011 · CA · contact PI
Career Development Program$107,998
P50 · FY2011 · CA · contact PI
Implications of Blockade of EGFR Axis & Src in Colorectal Cancer$329,683
P50 · FY2010 · CA · contact PI
Clinical Trials$165,134
P50 · FY2010 · CA · contact PI
Career Development Program$116,137
P50 · FY2010 · CA · contact PI
Implications of Blockade of EGFR Axis & Src in Colorectal Cancer$330,815
P50 · FY2009 · CA · contact PI
Clinical Trials$165,289
P50 · FY2009 · CA · contact PI
Career Development Program$118,644
P50 · FY2009 · CA · contact PI
Implications of Blockade of EGFR Axis & Src in Colorectal Cancer$331,970
P50 · FY2008 · CA · contact PI
Biological Effects of Calcitriol in Pancreatic Cancer$306,300
R21 · FY2008 · CA · contact PI
Integrated Assessment of Novel Therapies in Oncology$166,015
K24 · FY2008 · CA · contact PI
Clinical Trials$165,436
P50 · FY2008 · CA · contact PI
Career Development Program$121,173
P50 · FY2008 · CA · contact PI
Implications of Blockade of EGFR Axis & Src in Colorectal Cancer$305,651
P50 · FY2007 · CA · contact PI
Integrated Assessment of Novel Therapies in Oncology$166,015
K24 · FY2007 · CA · contact PI
Clinical Trials$152,691
P50 · FY2007 · CA · contact PI
Career Development Program$114,313
P50 · FY2007 · CA · contact PI
Vanderbilt Phase I Translational Research Program$100,037
U01 · FY2007 · CA · contact PI
Integrated Assessment of Novel Therapies in Oncology$166,015
K24 · FY2006 · CA · contact PI
Vanderbilt Phase I Translational Research Program$112,435
U01 · FY2006 · CA · contact PI
Integrated Assessment of Novel Therapies in Oncology$166,015
K24 · FY2005 · CA
Vanderbilt Phase I Translational Research Program$135,746
U01 · FY2005 · CA
Vanderbilt Phase I Translational Research Program$117,499
U01 · FY2004 · CA
Vanderbilt Phase I Translational Research Program$115,000
U01 · FY2003 · CA
INTEGRATED ASSESSMENT OF NOVEL THERAPIES IN ONCOLOGY$111,735
K24 · FY2003 · CA
INTEGRATED ASSESSMENT OF NOVEL THERAPIES IN ONCOLOGY$111,735
K24 · FY2002 · CA
OXALIPLATIN &IRINOTECAN IN PATIENTS W/ REFRACTORY SOLID TUMORS$0
M01 · FY2002 · RR
CORE--CLINICAL TRIALS CORE$0
P50 · FY2002 · CA
NX211 (LIPOSOMAL LURTOTECAN) IN SOLID ADVANCED TUMORS$0
M01 · FY2002 · RR
IRINOTECAN IN SOLID TUMOR PATIENTS WITH HEPATIC DYSFUNCTION$0
M01 · FY2002 · RR
TOPOISOMERASE I INHIBITOR J 107088 IN ADVANCED SOLID TUMORS$0
M01 · FY2002 · RR
INTEGRATED ASSESSMENT OF NOVEL THERAPIES IN ONCOLOGY$111,735
K24 · FY2001 · CA
IRINOTECAN IN SOLID TUMOR PATIENTS WITH HEPATIC DYSFUNCTION$0
M01 · FY2001 · RR
OXALIPLATIN &IRINOTECAN IN PATIENTS W/ REFRACTORY SOLID TUMORS$0
M01 · FY2001 · RR
OXALIPLATIN &IRINOTECAN IN PATIENTS W/ REFRACTORY SOLID TUMORS$0
M01 · FY2001 · RR
OXALIPLATIN &IRINOTECAN IN PATIENTS W/ REFRACTORY SOLID TUMORS$0
M01 · FY2001 · RR
NX211 (LIPOSOMAL LURTOTECAN) IN SOLID ADVANCED TUMORS$0
M01 · FY2001 · RR
NX211 (LIPOSOMAL LURTOTECAN) IN SOLID ADVANCED TUMORS$0
M01 · FY2001 · RR
NX211 (LIPOSOMAL LURTOTECAN) IN SOLID ADVANCED TUMORS$0
M01 · FY2001 · RR
TOPOISOMERASE I INHIBITOR J 107088 IN ADVANCED SOLID TUMORS$0
M01 · FY2001 · RR
TOPOISOMERASE I INHIBITOR J 107088 IN ADVANCED SOLID TUMORS$0
M01 · FY2001 · RR
TOPOISOMERASE I INHIBITOR J 107088 IN ADVANCED SOLID TUMORS$0
M01 · FY2001 · RR
IRINOTECAN IN SOLID TUMOR PATIENTS WITH HEPATIC DYSFUNCTION$0
M01 · FY2001 · RR
IRINOTECAN IN SOLID TUMOR PATIENTS WITH HEPATIC DYSFUNCTION$0
M01 · FY2001 · RR
INTEGRATED ASSESSMENT OF NOVEL THERAPIES IN ONCOLOGY$111,735
K24 · FY2000 · CA
OXALIPLATIN &IRINOTECAN IN PATIENTS W/ REFRACTORY SOLID TUMORS$592
M01 · FY2000 · RR
NX211 (LIPOSOMAL LURTOTECAN) IN SOLID ADVANCED TUMORS$0
M01 · FY2000 · RR
TOPOISOMERASE I INHIBITOR J 107088 IN ADVANCED SOLID TUMORS$0
M01 · FY2000 · RR
IRINOTECAN IN SOLID TUMOR PATIENTS WITH HEPATIC DYSFUNCTION$0
M01 · FY2000 · RR